Potential role of pharmacogenetics for optimalization of drug therapy in rheumatoid arthritis Kooloos, W.M.

The influence of a polymorphism at position -857 of the tumour necrosis factor alpha gene on clinical response to etaner- cept therapy in rheumatoid arthritis... Association of

In this paper we have presented a feasible pathway gene approach with defined selection criteria to effectively explore potential SNPs with adalimumab as a case study.. The

Abbreviations and accessory full names of formal genes can be relocated in the NCBI gene database (http://www.ncbi.nlm.nih.gov). b) P-values and odds ratios with 95%

Similarly as in chapter 5, both true predictive values observed in patients of the validation cohort were significantly lower compared to the values found in the original BeSt

and “Which factors could be of influence in the implementation of proven genetic associations in rheumatology clinical practice?” Furthermore, an ideal study proposal for a

Met deze hypothese werd in hoofdstuk 3 de relatie tussen SNPs in genen (DNA) coderend voor eiwitten, die betrokken zijn bij het vrijzetten van adeno- sine, en behandelingsuitkomst

External Validation of the Clinical Pharmacogenetic Model for predicting MTX monotherapy efficacy using a Swedish Cohort of patients with recent-onset rheumatoid arthritis..

‘Single nucleotide polymorphisms’ (SNPs) in genen coderend voor adenosine monopho- sphate deaminase (AMPD), 5-aminoimidazole-4-carboxamide transformylase (ATIC) en